Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this session, focusing on Ferric Maltol as a New Treatment Option- A Further Discussion on a New Perspective on Iron Deficiency Anemia (IDA). This discussion will build upon previous insights, offering a fresh perspective on how ferric maltol's unique properties are changing the clinical approach to IDA. The key new perspective lies in its ability to circumvent the common limitations of traditional oral iron supplements, particularly in patients with chronic inflammatory conditions.
A major challenge with conventional oral iron salts is their poor absorption and high incidence of gastrointestinal side effects, which is often exacerbated by inflammation. Ferric maltol offers a new paradigm by maintaining a stable and soluble complex of iron (Fe³⁺) and maltol, which prevents the formation of free iron in the gut. This minimizes irritation and oxidative stress, leading to superior gastrointestinal tolerability. This is crucial for patients with conditions like Inflammatory Bowel Disease (IBD), where traditional iron can worsen symptoms.
Therefore, get a comprehensive understanding of this new perspective on IDA management. This session will provide valuable insights into how ferric maltol's unique mechanism translates into better patient outcomes and adherence, particularly for those with a history of intolerance or non-response to conventional oral iron. Absorb the shared knowledge and follow Hidoc for more such indispensable sessions that keep you at the forefront of medical advancements.
See More Webinars @ Hidoc Webinars
1.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
2.
Why breast cancer survivors don't take their medicine, and what can be done about it.
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.
5.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
1.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
2.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
3.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
4.
Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?
5.
What Is Degos Disease? A Comprehensive Overview Of Symptoms, Diagnosis, and Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIII
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation